Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
| dc.contributor.author | Cutts J.C. | |
| dc.contributor.author | O’Flaherty K. | |
| dc.contributor.author | Zaloumis S.G. | |
| dc.contributor.author | Ashley E.A. | |
| dc.contributor.author | Chan J.A. | |
| dc.contributor.author | Onyamboko M.A. | |
| dc.contributor.author | Fanello C. | |
| dc.contributor.author | Dondorp A.M. | |
| dc.contributor.author | Day N.P. | |
| dc.contributor.author | Phyo A.P. | |
| dc.contributor.author | Dhorda M. | |
| dc.contributor.author | Imwong M. | |
| dc.contributor.author | Fairhurst R.M. | |
| dc.contributor.author | Lim P. | |
| dc.contributor.author | Amaratunga C. | |
| dc.contributor.author | Pukrittayakamee S. | |
| dc.contributor.author | Hien T.T. | |
| dc.contributor.author | Htut Y. | |
| dc.contributor.author | Mayxay M. | |
| dc.contributor.author | Abdul Faiz M. | |
| dc.contributor.author | Takashima E. | |
| dc.contributor.author | Tsuboi T. | |
| dc.contributor.author | Beeson J.G. | |
| dc.contributor.author | Nosten F. | |
| dc.contributor.author | Simpson J.A. | |
| dc.contributor.author | White N.J. | |
| dc.contributor.author | Fowkes F.J.I. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2023-06-18T17:47:19Z | |
| dc.date.available | 2023-06-18T17:47:19Z | |
| dc.date.issued | 2022-07-15 | |
| dc.description.abstract | Background. Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods. In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results. Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions. In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied. | |
| dc.identifier.citation | Journal of Infectious Diseases Vol.226 No.2 (2022) , 324-331 | |
| dc.identifier.doi | 10.1093/infdis/jiac232 | |
| dc.identifier.eissn | 15376613 | |
| dc.identifier.issn | 00221899 | |
| dc.identifier.pmid | 35703955 | |
| dc.identifier.scopus | 2-s2.0-85137126581 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/85715 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137126581&origin=inward | |
| oaire.citation.endPage | 331 | |
| oaire.citation.issue | 2 | |
| oaire.citation.startPage | 324 | |
| oaire.citation.title | Journal of Infectious Diseases | |
| oaire.citation.volume | 226 | |
| oairecerif.author.affiliation | WorldWide Antimalarial Resistance Network | |
| oairecerif.author.affiliation | Faculty of Tropical Medicine, Mahidol University | |
| oairecerif.author.affiliation | Mahidol Oxford Tropical Medicine Research Unit | |
| oairecerif.author.affiliation | Oxford University Clinical Research Unit | |
| oairecerif.author.affiliation | Melbourne School of Population and Global Health | |
| oairecerif.author.affiliation | The Peter Doherty Institute for Infection and Immunity | |
| oairecerif.author.affiliation | Ministry of Health Myanmar | |
| oairecerif.author.affiliation | Shoklo Malaria Research Unit | |
| oairecerif.author.affiliation | Monash University | |
| oairecerif.author.affiliation | National Institute of Allergy and Infectious Diseases (NIAID) | |
| oairecerif.author.affiliation | Mahosot Hospital, Lao | |
| oairecerif.author.affiliation | Faculty of Medicine, Nursing and Health Sciences | |
| oairecerif.author.affiliation | Nuffield Department of Medicine | |
| oairecerif.author.affiliation | Burnet Institute | |
| oairecerif.author.affiliation | Ehime University | |
| oairecerif.author.affiliation | University of Health Sciences | |
| oairecerif.author.affiliation | Myanmar Oxford Clinical Research Unit | |
| oairecerif.author.affiliation | Dev Care Foundation | |
| oairecerif.author.affiliation | Kinshasa School of Public Health |
